Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Malate Plus Hormonal Ablation Before Prostatectomy in High Risk Localized Prostate Cancer
NCT00329043Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2006
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started May 2006; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00329043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329043.